Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.55 |
| ▸ | CCR9 | P51686 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833794 | 0.89 | CNR2 (0.47) | CNR2PPARGALB | |
| SCHEMBL6834137 | 0.88 | CNR2 (0.52) | CCR2CNR2ALB | |
| SCHEMBL6834434 | 0.87 | CNR2 (0.50) | CNR2CNR1ALB | |
| SCHEMBL6833877 | 0.86 | CNR2 (0.45) | CCR2CNR2ALB | |
| SCHEMBL6833936 | 0.86 | CNR2 (0.47) | CCR2CCR9CNR2F10ALB | |
| SCHEMBL6834180 | 0.85 | CNR2 (0.53) | CNR2CNR1ALB | |
| SCHEMBL6835700 | 0.85 | CNR2 (0.48) | CNR2ALB | |
| SCHEMBL6833160 | 0.85 | CCR2 (0.61) | CCR2ROCK1PPARGF10 | |
| SCHEMBL6833761 | 0.85 | ECE1 (0.47) | CCR2CNR2CNR1ALB | |
| SCHEMBL6830403 | 0.84 | CNR2 (0.55) | CNR2CNR1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CCR2 3933/4885CCR9 4483/4885CNR2 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.